Massachusetts General Hospital and Brigham and Women’s Hospital will use $50 million to study treatments for suicidality and bipolar disorder.
The funding is from the Patient-Centered Outcomes Research Institute, a nonprofit supplier of medical research grants based in Washington, DC.
"The studies have the potential to fill important evidence gaps relevant to a range of healthcare decision makers and help them better assess their care options. We look forward to following the studies' progress and working with the research teams to share their results," Nakela Cook, MD, MPH, executive director of the institute, said in a July 26 Mass General Brigham news release.
Bringham and Women's researchers, led by Amit Anand, MD, director of translational clinical trials in the department of psychiatry, will get more than $28.5 million in funding for national studies comparing electroconvulsive therapy and intravenous ketamine treatments for acute suicidal depressed state.
Massaccussett General's researchers, led by Andrew Nierenberg, MD, director of the Dauten Family Center for bipolar treatment innovation, and Andrea Foulkes, PhD, director of biostatistics center at the hospital, will be given about $25 million to compare four medication treatments for bipolar disorder: cariprazine, lurasidone, quetiapine, and a combination of an antipsychotic and antidepressant.